1276681-48-1

Basic information

• Product Name: 1,1,1-trifluoro-2-{1-[3-(4-fluorophenyl)-2-hydroxymethylindolizin-7-ylmethyl]-1H-[1,2,3]triazol-4-yl}butan-2-ol
• Synonyms: 1,1,1-trifluoro-2-{1-[3-(4-fluorophenyl)-2-hydroxymethylindolizin-7-ylmethyl]-1H-[1,2,3]triazol-4-yl}butan-2-ol
• CAS NO: 1276681-48-1
• Molecular Weight: 448.42
• Mol File: 1276681-48-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,1,1-trifluoro-2-{1-[3-(4-fluorophenyl)-2-hydroxymethylindolizin-7-ylmethyl]-1H-[1,2,3]triazol-4-yl}butan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1,1-trifluoro-2-{1-[3-(4-fluorophenyl)-2-hydroxymethylindolizin-7-ylmethyl]-1H-[1,2,3]triazol-4-yl}butan-2-ol(1276681-48-1)
• EPA Substance Registry System: 1,1,1-trifluoro-2-{1-[3-(4-fluorophenyl)-2-hydroxymethylindolizin-7-ylmethyl]-1H-[1,2,3]triazol-4-yl}butan-2-ol(1276681-48-1)

Safety Data

• Hazardous Substances Data: 1276681-48-1(Hazardous Substances Data)

Upstream product

• 1276680-64-8 3-(4-fluorophenyl)-7-[4-(1-hydroxy-1-trifluoromethylpropyl)[1,2,3]triazol-1-ylmethyl]indolizine-2-carboxylic acid ethyl ester 
• 1276680-69-3 7-azidomethyl-3-(4-fluorophenyl)indolizine-2-carboxylic acid ethyl ester 
• 1276680-68-2 3-(4-fluorophenyl)-7-methanesulfonyloxymethylindolizine-2-carboxylic acid ethyl ester 
• 1276680-67-1 3-(4-fluorophenyl)-7-hydroxymethylindolizine-2-carboxylic acid ethyl ester 
• 1276680-66-0 7-hydroxymethylindolizine-2-carboxylic acid ethyl ester 
• 1276680-65-9 7-(tert-butyldimethylsilanyloxymethyl)indolizine-2-carboxylic acid ethyl ester 
• 1006302-00-6 4-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-pyridine 
• 1044277-02-2 3-(trifluoromethyl)-1-(trimethylsilyl)pent-1-yn-3-ol 
• 16830-24-3 methyl 2-methylisonicotinate 
• 105250-16-6 (2-methylpyridin-4-yl)methanol 
• 22282-99-1 4-bromo-2-methylpyridine 

Relevant articles and documents

INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.